The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women

dc.authorscopusid55597937800
dc.authorscopusid23968920100
dc.authorscopusid6506061779
dc.authorscopusid57191926529
dc.authorscopusid55956325000
dc.authorscopusid55481926000
dc.contributor.authorÇelik, E.
dc.contributor.authorGüzel, Savaş
dc.contributor.authorAbalı, Remzi
dc.contributor.authorYıldırım Güzelant, Aliye
dc.contributor.authorGüzel, Eda Çelik
dc.contributor.authorKüçükyalçın, Volkan
dc.date.accessioned2022-05-11T14:10:03Z
dc.date.available2022-05-11T14:10:03Z
dc.date.issued2013
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalı
dc.description.abstractAim. A lack of estrogen in postmenopausal women is an important factor causing the development of osteoporosis. Our purpose is to investigate the effects of Fibroblast Growth Factor 23 (FGF-23) on bone mineral metabolism and bone turnover. Methods. Twenty-eight patients with postmenopausal osteoporosis (PMO), 32 patients with postmenopausal osteopenia and 30 healthy control subjects (postmenopausal non-osteoporosis) were included in this study. In order to assess the bone mineral metabolism; FGF 23, parathyroid hormone, vitamin D, calcium, phosphate, osteocalcin, alkaline phosphatase and hydroxyproline levels were measured. Results. FGF 23 levels were found significantly higher in PMO group compared with postmenopausal osteopenia and control groups (P<0.01 and P<0.05 respectively). Urine hydroxyproline level was detected to be significantly lower in PMO patients compared with control group (P<0.01). Lomber and femur BMD levels were found to be significantly lower in PMO patients compared with postmenopausal osteopenia and control groups (P<0.001, P<0.001; P<0.001, P<0.001 respectively). On the other hand, when we categorized the PMO group subjects according to the age of menopause, the FGF 23 levels were found to be significantly higher in the group of menopausal age <5 years compared to the group of menopausal age >10 and to the group of menopausal age 5-10 years (P<0.05, P<0.05). Conclusion. We think our findings indicate that serum FGF 23 level is a significant determinant of increased bone turnover at early periods in PMO patients.
dc.description.sponsorshipNamik Kemal UniversityNamik Kemal University
dc.description.sponsorshipThis study was supported by Namik Kemal University Scientific Research Funding.
dc.identifier.endpage504
dc.identifier.issn0026-4806
dc.identifier.issn1827-1669
dc.identifier.issue5en_US
dc.identifier.pmid24101107
dc.identifier.scopus2-s2.0-84890016966
dc.identifier.scopusqualityQ2
dc.identifier.startpage497
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5264
dc.identifier.volume104
dc.identifier.wosWOS:000327753900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÇelik, E.
dc.institutionauthorGüzel, S.
dc.institutionauthorAbalı, Remzi
dc.institutionauthorGüzelant, A. Y.
dc.institutionauthorGüzel, E. Çelik
dc.institutionauthorKücükyalçın, V.
dc.language.isoen
dc.publisherEdizioni Minerva Medica
dc.relation.ispartofMinerva Medica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFibroblast growth factor 23
dc.subjectOsteoporosis, postmenopausal
dc.subjectOsteocalcin
dc.subjectHydroxyproline
dc.subjectVitamin D
dc.subjectVitamin-D
dc.subjectParathyroid-Hormone
dc.subjectBone Turnover
dc.subjectSex Steroids
dc.subjectEstrogen
dc.subjectFgf-23
dc.subjectFgf23
dc.subjectMice
dc.subjectRat
dc.subjectFibroblast-Growth-Factor-23
dc.titleThe relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women
dc.typeArticle

Dosyalar